Generation and Accumulation of Various Advanced Glycation End-Products in Cardiomyocytes May Induce Cardiovascular Disease

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(13), P. 7319 - 7319

Published: July 3, 2024

Cardiomyocyte dysfunction and cardiovascular diseases (CVDs) can be classified as ischemic or non-ischemic. We consider the induction of cardiac tissue by intracellular advanced glycation end-products (AGEs) in cardiomyocytes a novel type non-ischemic CVD. Various types AGEs generated from saccharides (glucose fructose) their intermediate/non-enzymatic reaction byproducts. Recently, certain (

Language: Английский

Mitochondrial Dysfunction as a Therapeutic Target in Diabetic Cardiomyopathy: Progress and Prospects

Cardiovascular Innovations and Applications, Journal Year: 2025, Volume and Issue: 10(1)

Published: Jan. 1, 2025

Diabetic cardiomyopathy (DCM) is a specific type of that independent hypertension and coronary artery disease, closely associated with the high incidence mortality heart failure in people diabetes. DCM causes microvascular myocardial metabolic disorder, fibrosis, thereby leading to left ventricular remodeling, diastolic and/or systolic dysfunction, eventually progressing congestive failure. Recent studies have highlighted crucial roles mitochondrial dysfunction pathogenesis DCM, including aspects such as glucose-lipid oxidative stress damage, calcium regulation respiratory chain uncoupling, kinetic imbalance, DNA damage. Increasing numbers targets drugs are being identified ameliorate consequently slow progression. This article reviews newly past decade, provide new insights for prevention treatment.

Language: Английский

Lipotoxicity as a therapeutic target in the type 2 diabetic heart

Journal of Molecular and Cellular Cardiology, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 1, 2025

Language: Английский